Larvol Delta - Black-Diamond-Therapeutics-Announces-Initial-Phase-2-Data-Demonstrating-Robust-Antitumor-Activity-of-BDTX1535-in-Patients-with-Recurrent-EGFRm-NSCLC-who-Present-with-a-Broad-Spectrum-of-Classical-Nonclassical-and-C797S-Resistance-Mutations

BDTX-1535 - Black Diamond Therap

https://www.globenewswire.com/en/news-release/2024/09/23/2951227/0/en/Black-Diamond-Therapeutics-Announces-Initial-Phase-2-Data-Demonstrating-Robust-Anti-tumor-Activity-of-BDTX-1535-in-Patients-with-Recurrent-EGFRm-NSCLC-who-Present-with-a-Broad-Spec.html

Sep 23, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next